The influence of finasteride on the development of prostate cancer.
By Ian M. Thompson, P. Goodman, C. Tangen, M. Lucia, G. Miller, Leslie G. Ford, Michael M. Lieber, R. Cespedes, J. Atkins, S. Lippman and 5 more. New England Journal of Medicine, 2003
2,602 citations recorded by the source corpus.
Subfields: Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/15a508cd4adb969e8e9ad326e01e4b8c4d08cb69
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. (2006, background): “8% over a 7-year period, but apparently, cancers with Gleason grade from 7 to 10 were more common in the Finasteride arm than in the placebo arm (30).”
- Polyamines and cancer: old molecules, new understanding (2004, background): “However, more high-grade tumours were detected in the finasteride treatment group, raising the concern that these might be a consequence of drug us”
- Advances in male contraception. (2008, result): “Moreover, results from the Prostate Cancer Prevention Trial (293) suggest that 5 -reductase inhibition may have longterm benefits for men by reducing prostate cancer incidence.”
- Serum Sex Steroids Depict a Nonlinear U-Shaped Association with High-Risk Prostate Cancer at Radical Prostatectomy (2012, background): “Translationally, the 2 largest trials that investigated the use of 5ARIs showed an overall relative reduction of 23% to 25% in prostate cancer diagnoses, with an absolute increase in the incidence of high-grade prostate cancer in the chemoprevention group in both trials (48, 49).”
- Changes in circulating microRNA levels associated with prostate cancer (2012, background): “While community prostate-specific antigen (PSA) testing can lead to the early detection and diagnosis of prostate cancer this test has a low specificity, and the optimal threshold for biopsy is unclear (Thompson et al, 2003).”
- The decline of androgen levels in elderly men and its clinical and therapeutic implications. (2005, background): “As to the use of inhibitors of the 5 -reductase in men with benign prostate hypertrophy, treatment with finasteride results in slightly elevated serum LH and testosterone levels (237), but the treatment mitigates androgenic effects in those tissues that are largely dependent on local production of D”
- Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) (2008, neutral): “Smoking status Never 3682 (42) 3752 (43) 3780 (43) 3666 (42)”
- Erectile dysfunction and subsequent cardiovascular disease. (2005, neutral): “Age, mean (SD), y 62 (6) 61 (5) 64 (6)”
- Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. (2005, methodology): “0 ng/mL to receive either finasteride or placebo for 7 years.(14) Measurement of PSA levels and digital rectal examination were performed annually.”
- Obesity and cancer risk: Emerging biological mechanisms and perspectives. (2019, background): “Men treated with finasteride, a 5a-reductase inhibitor that decreases dihydrotestosterone levels, displayed an increased risk for high-grade and decreased risk for well-differentiated prostate cancer [96].”